传奇生物第四季度每股收益较分析师预期低0.06美元，而收入同比增长187.6%。 Legend Biotech Q4 EPS missed analyst estimate by $0.06, while revenue rose 187.6% YoY.

传奇生物科技 (LEGN) 报告第四季度每股收益 (EPS) 为 (0.40 美元)，比分析师预期低 0.06 美元，而收入为 7,946 万美元，而市场普遍预期为 9,407 万美元。 Legend Biotech (LEGN) reported Q4 EPS of ($0.40), missing the analyst estimate by $0.06, while revenue came in at $79.46M vs the consensus estimate of $94.07M. 这使得收入比上年增长了 187.6%。 This resulted in a 187.6% rise in revenue from the previous year. 然而，该公司的盈利从-13587.6万美元增加到-14481.8万美元。 The company's earnings, however, increased from -$135.876M to -$144.818M.